RELAFEN (nabumetone) is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic properties in pharmacologic studies. As with other non-steroidal anti-inflammatory agents, its mode of action is not known; however, the ability to inhibit prostaglandin synthesis may be involved in the anti-inflammatory effect.
The parent compound is a prodrug, which undergoes hepatic biotransformation
to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent
inhibitor of prostaglandin synthesis.
It is acidic and has an n-octanol:phosphate buffer partition coefficient of
0.5 at pH 7.4.
Pharmacokinetics: After oral administration, approximately 80% of a
radiolabelled dose of nabumetone is found in the urine, indicating that nabumetone
is well absorbed from the gastrointestinal tract. Nabumetone itself is not detected
in the plasma because, after absorption, it undergoes rapid biotransformation
to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA).
Approximately 35% of a 1,000-mg oral dose of nabumetone is converted to 6MNA
and 50% is converted into unidentified metabolites which are subsequently excreted
in the urine. Following oral administration of RELAFEN (nabumetone) , 6MNA exhibits pharmacokinetic
characteristics that generally follow a one-compartment model with first order
input and first order elimination.
6MNA is more than 99% bound to plasma proteins. The free fraction is dependent on total concentration of 6MNA and is proportional to dose over the range of 1,000 mg to 2,000 mg. It is 0.2% to 0.3% at concentrations typically achieved following administration of 1,000 mg of RELAFEN (nabumetone) and is approximately 0.6% to 0.8% of the total concentrations at steady state following daily administration of 2,000 mg.
Steady-state plasma concentrations of 6MNA are slightly lower than predicted from single-dose data. This may result from the higher fraction of unbound 6MNA which undergoes greater hepatic clearance.
Coadministration of food increases the rate of absorption and subsequent appearance of 6MNA in the plasma but does not affect the extent of conversion of nabumetone into 6MNA. Peak plasma concentrations of 6MNA are increased by approximately one third.
Coadministration with an aluminum-containing antacid had no significant effect on the bioavailability of 6MNA.
Table 1. Mean Pharmacokinetic Parameters of Nabumetone Active
Metabolite (6MNA) at Steady State Following Oral Administration of 1,000-mg
or 2,000-mg Doses of RELAFEN (nabumetone)
| Young Adults
Mean ± SD
n = 31
| Young Adults
Mean ± SD
n = 12
Mean ± SD
n = 27
| Tmax (hr)
|| 3.0 (1.0 to 12.0)
|| 2.5 (1.0 to 8.0)
|| 4.0 (1.0 to 10.0)
| t½ (hr)
|| 22.5 ± 3.7
|| 26.2 ± 3.7
|| 29.8 ± 8.1
| CLss/F (mL/min)
|| 26.1 ± 17.3
|| 21.0 ± 4.0
|| 18.6 ± 13.4
| VDss/F (L)
|| 55.4 ± 26.4
|| 53.4 ± 11.3
|| 50.2 ± 25.3
The simulated curves in the graph below illustrate the range of active metabolite
plasma concentrations that would be expected from 95% of patients following
1,000-mg to 2,000-mg doses to steady state. The cross-hatched area represents
the expected overlap in plasma concentrations due to intersubject variation
following oral administration of 1,000 mg to 2,000 mg of RELAFEN (nabumetone) .
6MNA undergoes biotransformation in the liver, producing inactive metabolites that are eliminated as both free metabolites and conjugates. None of the known metabolites of 6MNA has been detected in plasma. Preliminary in vivo and in vitro studies suggest that unlike other NSAIDs, there is no evidence of enterohepatic recirculation of the active metabolite. Approximately 75% of a radiolabelled dose was recovered in urine in 48 hours. Approximately 80% was recovered in 168 hours. A further 9% appeared in the feces. In the first 48 hours, metabolites consisted of:
| -nabumetone, unchanged
|| not detectable
| -6-methoxy-2-naphthylacetic acid (6MNA), unchanged
| -6MNA, conjugated
| -6-hydroxy-2-naphthylacetic acid (6HNA), unchanged
| -6HNA, conjugated
| -4-(6-hydroxy-2-naphthyl)-butan-2-ol, Conjugated
| -O-desmethyl-nabumetone, conjugated
| -unidentified minor metabolites
| Total % Dose:
Following oral administration of dosages of 1,000 mg to 2,000 mg to steady state, the mean plasma clearance of 6MNA is 20 to 30 mL/min and the elimination half-life is approximately 24 hours.
Elderly Patients: Steady-state plasma concentrations in elderly patients
were generally higher than in young healthy subjects (see Table 1 for summary
of pharmacokinetic parameters).
Renal Insufficiency: In moderate renal insufficiency patients (creatinine
clearance 30 to 49 mL/min), the terminal half-life of 6MNA was increased by
approximately 50% (39.2 ± 7.8 hrs, N=12) compared to the normal subjects
(26.9 ± 3.3 hrs, N=13), and there was a 50% increase in the plasma levels
of unbound 6MNA.
Additionally, the renal excretion of 6MNA in the moderate renal impaired patients
decreased on average by 33% compared to that in the normal patients. A similar
increase in the mean terminal half-life of 6MNA was seen in a small study of
patients with severe renal dysfunction (creatine clearance <30 mL/min). In
patients undergoing hemodialysis, steady-state plasma concentrations of the
active metabolite 6MNA were similar to those observed in healthy subjects. Due
to extensive protein binding, 6MNA is not dialyzable.
Dosage adjustment of RELAFEN (nabumetone) generally is not necessary in patients with mild
renal insufficiency (≥ 50 mL/min). Caution should be used in prescribing
RELAFEN (nabumetone) to patients with moderate or severe renal insufficiency. The maximum
starting doses of RELAFEN (nabumetone) in patients with moderate or severe renal insufficiency
should not exceed 750 mg or 500 mg, respectively once daily. Following careful
monitoring of renal function in patients with moderate or severe renal insufficiency,
daily doses may be increased to a maximum of 1,500 mg and 1,000 mg, respectively
(see WARNINGS, Renal Effects).
Hepatic Impairment: Data in patients with severe hepatic impairment
are limited. Biotransformation of nabumetone to 6MNA and the further metabolism
of 6MNA to inactive metabolites is dependent on hepatic function and could be
reduced in patients with severe hepatic impairment (history of or biopsy-proven
Special Studies: Gastrointestinal: RELAFEN (nabumetone) was compared
to aspirin in inducing gastrointestinal blood loss. Food intake was not monitored.
Studies utilizing 51Cr-tagged red blood cells in healthy males showed no difference
in fecal blood loss after 3 or 4 weeks' administration of 1,000 mg or 2,000
mg of RELAFEN (nabumetone) daily when compared to either placebo-treated or nontreated subjects.
In contrast, aspirin 3,600 mg daily produced an increase in fecal blood loss
when compared to subjects who received RELAFEN (nabumetone) , placebo, or no treatment. The
clinical relevance of the data is unknown.
The following endoscopy trials entered patients who had been previously treated with NSAIDs. These patients had varying baseline scores and different courses of treatment. The trials were not designed to correlate symptoms and endoscopy scores. The clinical relevance of these endoscopy trials, i.e., either G.I. symptoms or serious G.I. events, is not known.
Ten endoscopy studies were conducted in 488 patients who had baseline and post-treatment endoscopy. In 5 clinical trials that compared a total of 194 patients on 1,000 mg of RELAFEN (nabumetone) daily or naproxen 250 mg or 500 mg twice daily for 3 to 12 weeks, treatment with RELAFEN (nabumetone) resulted in fewer patients with endoscopically detected lesions (>3 mm). In 2 trials a total of 101 patients administered 1,000 mg or 2,000 mg of RELAFEN (nabumetone) daily or piroxicam 10 mg to 20 mg for 7 to 10 days, there were fewer patients treated with RELAFEN (nabumetone) with endoscopically detected lesions. In 3 trials of a total of 47 patients on 1,000 mg of RELAFEN (nabumetone) daily or indomethacin 100 mg to 150 mg daily for 3 to 4 weeks, the endoscopy scores were higher with indomethacin. Another 12-week trial in a total of 171 patients compared the results of treatment with 1,000 mg of RELAFEN (nabumetone) daily to ibuprofen 2,400 mg/day and ibuprofen 2,400 mg/day plus misoprostol 800 mcg/day. The results showed that patients treated with RELAFEN (nabumetone) had a lower number of endoscopically detected lesions (>5 mm) than patients treated with ibuprofen alone but comparable to the combination of ibuprofen plus misoprostol. The results did not correlate with abdominal pain.
Other: In 1-week, repeat-dose studies in healthy volunteers, 1,000 mg
of RELAFEN (nabumetone) daily had little effect on collagen-induced platelet aggregation
and no effect on bleeding time. In comparison, naproxen 500 mg daily suppressed
collagen-induced platelet aggregation and significantly increased bleeding time.
Osteoarthritis: The use of RELAFEN (nabumetone) in relieving the signs and symptoms
of osteoarthritis (OA) was assessed in double-blind, controlled trials in which
1,047 patients were treated for 6 weeks to 6 months. In these trials, RELAFEN (nabumetone)
in a dose of 1,000 mg/day administered at night was comparable to naproxen 500
mg/day and to aspirin 3,600 mg/day.
Rheumatoid Arthritis: The use of RELAFEN (nabumetone) in relieving the signs and
symptoms of rheumatoid arthritis (RA) was assessed in double-blind, randomized,
controlled trials in which 770 patients were treated for 3 weeks to 6 months.
RELAFEN (nabumetone) , in a dose of 1,000 mg/day administered at night, was comparable to
naproxen 500 mg/day and to aspirin 3,600 mg/day.
In controlled clinical trials of rheumatoid arthritis patients, RELAFEN (nabumetone) has been used in combination with gold, d-penicillamine, and corticosteroids.
Patient Exposure in Clinical Trials of Osteoarthritis and Rheumatoid Arthritis:
In clinical trials with osteoarthritis and rheumatoid arthritis patients, most patients responded to RELAFEN (nabumetone) in doses of 1,000 mg/day administered nightly; total daily dosages up to 2,000 mg were used. In open-labelled studies, 1,490 patients were permitted dosage increases and were followed for approximately 1 year (mode). Twenty percent of patients (n = 294) were withdrawn for lack of effectiveness during the first year of these open-labelled studies. The following table provides patient-exposure to doses used in the US clinical trials:
Table 2. Clinical Double-Blinded and Open-Labelled Trials
of RELAFEN (nabumetone) in Osteoarthritis and Rheumatoid Arthritis
| Dose of RELAFEN
|| Number of Patients
|| Mean/Mode Duration of Treatment (yr)
| 500 mg
| 1,000 mg
| 1,500 mg
| 2,000 mg
As with other NSAIDs, the lowest dose should be sought for each patient. Patients weighing under 50 kg may be less likely to require dosages beyond 1,000 mg; therefore, after observing the response to initial therapy, the dose should be adjusted to meet individual patients' requirements.